All About Drugs

Tout sur les médicaments הכל על תרופות كل شيئ عن الأدوية Все о наркотиках 关于药品的一切 డ్రగ్స్ గురించి అన్ని 마약에 관한 모든 것 Όλα για τα Ναρκωτικά Complete Tracking of Drugs Across the World by Dr Anthony Melvin Crasto, Worldpeacepeaker, worlddrugtracker, PH.D (ICT), MUMBAI, INDIA, Worlddrugtracker, Helping millions, 9 million hits on google on all websites, 2.5 lakh connections on all networks, “ALL FOR DRUGS” CATERS TO EDUCATION GLOBALLY, No commercial exploits are done or advertisements added by me. This is a compilation for educational purposes only. P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent

Permalink Uncategorized Comments Off

May 282013

Rituximab (trade names Rituxan and MabThera) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells. Rituximab destroys B cells, and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.

Rituxan

Tiny Biotech Developing Drugs Akin To Biogen’s Rituxan Seen As Potential …
Forbes
One small biopharmaceutical that believes it has a proven technology for another blockbuster is TG Therapeutics (TGTX), which is focused on developing drugs for the treatment of cancer and other underserved therapeutic needs, including hematologic …read all

http://www.forbes.com/sites/genemarcial/2013/05/27/tiny-biotech-developing-drugs-akin-to-biogens-rituxan-seen-as-potential-buyout-bet/

Basilea reports isavuconazole orphan drug designation by US FDA

orphan status Comments Off

May 282013

isavuconazonium as sulfate

Isavuconazole (BAL4815) is a triazole antifungal. Its prodrug, Isavuconazonium sulfate (BAL8557) is currently in Phase III clinical trials.

Basilea reports isavuconazole orphan drug designation by US FDA
ITNews
Pharmaceutica AG / Basilea reports isavuconazole orphan drug designation by U.S. FDA .

Basel, Switzerland, May 28, 2013 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of invasive aspergillosis. An FDA orphan drug designation provides several benefits to the sponsor including a seven-year market exclusivity from product approval in the U.S. Isavuconazole was previously granted FDA fast track status that is designed to facilitate development and expedite the review of drugs to treat serious diseases

Isavuconazole (drug substance: isavuconazonium sulfate) is an investigational intravenous and oral broad-spectrum antifungal.

In collaboration with Astellas Pharma Inc., isavuconazole is being investigated in phase 3 clinical … read all at

http://www.itnews.it/news/2013/0528071501820/basilea-reports-isavuconazole-orphan-drug-designation-by-u-s-fda.html

DRUG MANUFACTURING PRESENTATION-PROCESSES

MANUFACTURING Comments Off

May 282013

http://newdrugapprovals.wordpress.com/2013/05/28/drug-manufacturing-presentation-processes/

DRUG MANUFACTURING PRESENTATION-PROCESSES

DRUGS-PROCESS CHEMISTRY OVERVIEW

PROCESS Comments Off

May 282013

http://newdrugapprovals.wordpress.com/2013/05/28/drugs-process-chemistry-overview/

Sonepcizumab/LT1009-US-based Lpath has begun patient dosing in Phase 2a single-arm trial of anti-cancer drug, Asonep.

phase 2 Comments Off

May 282013

http://newdrugapprovals.wordpress.com/2013/05/28/sonepcizumablt1009-us-based-lpath-has-begun-patient-dosing-in-phase-2a-single-arm-trial-of-anti-cancer-drug-asonep/

Newer Entries

Categories

DR ANTHONY MELVIN CRASTO Ph.D amcrasto@gmail.com

MOBILE-+91 9323115463

GLENMARK SCIENTIST , NAVIMUMBAI, INDIA

……………………………………. DR ANTHONY MELVIN CRASTO Ph.D , Born in Mumbai in 1964 and graduated from Mumbai University, Completed his PhD from ICT ,1991, Mumbai, India in Organic chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARKPHARMA LTD, Research centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Prior to joining Glenmark, he worked with major multinationals like Hoechst Marion Roussel, now Sanofi Aventis, & Searle India ltd, now Rpg lifesciences, etc. He has worked in Basic research, Neutraceuticals, Natural products, Flavors, Fragrances, Pheromones, Vet Drugs, Drugs, formulation, GMP etc. He has total 25 yrs exp in this field, he is now helping millions, has 9 million hits on google on all organic chemistry websites. His New Drug Approvals , Green Chemistry International, Eurekamoments in Organic Chemistry , Organic Chemistry by Dr Anthony, WIX BLOG , are some most read chemistry blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 29 year tenure, good knowledge of IPM, GMP, Regulatory aspects, he has several international drug patents published worldwide . He has good proficiency in Technology Transfer, Spectroscopy , Stereochemistry , Synthesis, Reactions in Org Chem , Polymorphism, Pharmaceuticals , Medicinal chemistry , Organic chemistry literature , Patent related site , Green chemistry , Reagents , R & D , Molecules , Heterocyclic chem , Sourcing etc He suffered a paralytic stroke in dec 2007 and is bound to a wheelchair, this seems to have injected feul in him to help chemists around the world, he is more active than before and is pushing boundaries, he has 2.5 lakh connections on all networking sites, He makes himself available to all, contact him on +91 9323115463, amcrasto@gmail.com